Abbott closes $890m acquisition of Cardiovascular Systems

TAGS

Abbott has closed the previously announced $890 million acquisition of , Inc. (CSI), which has developed an atherectomy system for the treatment of peripheral and coronary artery disease.

As per the terms of the deal announced in February 2023, Cardiovascular Systems’ stockholders were offered $20 per share by .

Cardiovascular Systems, which was trading on Nasdaq prior to the deal, has now become a fully-owned subsidiary of the healthcare major.

See also  Trump's shocking promise: Return of Muslim travel ban in 2024 presidential bid

Based in , Cardiovascular Systems is engaged in making devices for atherectomy, which is a minimally invasive treatment for plaque build-up in arteries that can curb the flow of blood.

Abbott closes $890m acquisition of Cardiovascular Systems

Abbott closes $890m acquisition of Cardiovascular Systems. Photo courtesy of Abbott.

Atherectomy may enhance the efficacy of traditional balloon angioplasty or stent procedures to restore blood flow in complicated arterial diseases.

See also  Togetherall bags $10m investment for online mental health platform from FPE

Cardiovascular Systems has an early-stage pipeline of complementary intervention devices as well that are in the process of being developed.

— Abbott executive vice president of Medical Devices said: “For patients with complex cardiovascular disease, new and innovative therapies such as CSI’s leading atherectomy system are an opportunity to live better, fuller lives.

See also  Sacklers forced to pay $7.4bn as Purdue Pharma fights opioid crisis lawsuits

“The acquisition of CSI is a component of an overall investment in our vascular portfolio that enhances our ability to care for patients with peripheral and coronary artery disease.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This